TRIM25 in Septic Patients

Expression of Trim25 in Peripheral Blood Mononuclear Cells of Patients With Sepsis and Non-sepsis and Its Relationship With the Prognosis of Patients With Sepsis

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07320638

Enrollment

Registered

2026-01-06

Start date

2021-12-10

Completion date

2026-07-01

Last updated

2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

Sepsis is a life-threatening condition caused by the body's overwhelming response to infection, which can lead to organ damage and failure. The goal of this observational study is to better understand the underlying biological changes that occur in patients with sepsis compared to those who do not have the condition. We will collect peripheral blood samples from patients diagnosed with sepsis and from non-sepsis control participants. From these samples, we will isolate peripheral blood mononuclear cells (PBMCs) and serum. We will then analyze these components to measure the activity of specific genes and the levels of key inflammatory factors (cytokines). The information we gather will help researchers identify molecular and inflammatory markers associated with sepsis. This knowledge is crucial for developing new and more effective methods for diagnosing and treating this critical illness.

Interventions

DIAGNOSTIC_TESTGene and Inflammatory Marker Analysis in Sepsis

1.Sepsis Group: 1. SOFA score \>=2; 2. Aged 18-70 years male and female; 3. Hospitalization. 2.Non-sepsis Group: (1) Healthy adults; (2) Aged 18-70 years male and female.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* 1\. SOFA score \>=2; 2. Aged 18-70 years male and female; 3. Hospitalization.

Exclusion criteria

* 1\. Immune system disease, such as HIV; 2. Disease that possibly affect the function of immune system, such as tumor and chronic viral infection; 3. Patients that treated with massive cortical hormone (\>200mg/d) or immunosuppressant; 4. Pregnant or lactation women.

Design outcomes

Primary

Measure	Time frame	Description
TRIM25 in PBMCs	From 2021.12 to 2026.06	We will collect peripheral blood mononuclear cells (PBMCs) from both sepsis patients and non-sepsis control patients to compare the expression level of the TRIM25 gene in these cells.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026